HK1188782A1 - Substituted sodium-1h-pyrazole-5-olate 1h--5- - Google Patents

Substituted sodium-1h-pyrazole-5-olate 1h--5-

Info

Publication number: HK1188782A1
Authority: HK; Hong Kong
Prior art keywords: olate; pyrazole; substituted sodium; substituted; sodium
Prior art date: 2010-11-18

Application number

HK14101861.8A

Other languages

English (en)

Chinese (zh)

Inventor

Hans-Christian Militzer

Jrg GRIES

Stefan Koep

Original Assignee

Bayer Ip Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-11-18

Filing date

2014-02-26

Publication date

2014-05-16

2014-02-26 Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh

2014-05-16 Publication of HK1188782A1 publication Critical patent/HK1188782A1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Cardiology (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Immunology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Transplantation (AREA)
Psychology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)

HK14101861.8A 2010-11-18 2014-02-26 Substituted sodium-1h-pyrazole-5-olate 1h--5- HK1188782A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE102010044131A DE102010044131A1 (de)	2010-11-18	2010-11-18	Substituiertes Natrium-1H-pyrazol-5-olat
PCT/EP2011/070099 WO2012065967A1 (de)	2010-11-18	2011-11-15	Substítuiertes natrium-1h-pyrazol-5-olat

Publications (1)

Publication Number	Publication Date
HK1188782A1 true HK1188782A1 (en)	2014-05-16

Family

ID=44999768

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HK14101861.8A HK1188782A1 (en)	2010-11-18	2014-02-26	Substituted sodium-1h-pyrazole-5-olate 1h--5-
HK15111529.0A HK1210776A1 (en)	2010-11-18	2015-11-23	Substituted sodium 1h-pyrazol-5-olate 1h--5-

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
HK15111529.0A HK1210776A1 (en)	2010-11-18	2015-11-23	Substituted sodium 1h-pyrazol-5-olate 1h--5-

Country Status (45)

Country	Link
US (2)	US8653074B2 (xx)
EP (1)	EP2640718B8 (xx)
JP (1)	JP5918779B2 (xx)
KR (2)	KR101984317B1 (xx)
CN (2)	CN103270031B (xx)
AP (1)	AP3429A (xx)
AR (1)	AR083887A1 (xx)
AU (1)	AU2011331305B2 (xx)
BR (1)	BR112013012223B1 (xx)
CA (1)	CA2818002C (xx)
CL (1)	CL2013001390A1 (xx)
CO (1)	CO6741155A2 (xx)
CR (1)	CR20130196A (xx)
CU (1)	CU20130072A7 (xx)
CY (1)	CY1120375T1 (xx)
DE (1)	DE102010044131A1 (xx)
DK (1)	DK2640718T3 (xx)
DO (1)	DOP2013000096A (xx)
EA (1)	EA023103B1 (xx)
EC (1)	ECSP13012627A (xx)
ES (1)	ES2675580T3 (xx)
GT (1)	GT201300125A (xx)
HK (2)	HK1188782A1 (xx)
HR (1)	HRP20180993T1 (xx)
HU (1)	HUE038024T2 (xx)
IL (1)	IL226192A (xx)
JO (1)	JOP20110347B1 (xx)
LT (1)	LT2640718T (xx)
MA (1)	MA34671B1 (xx)
MX (1)	MX347670B (xx)
MY (1)	MY167219A (xx)
NZ (1)	NZ610614A (xx)
PE (2)	PE20140391A1 (xx)
PL (1)	PL2640718T3 (xx)
PT (1)	PT2640718T (xx)
RS (1)	RS57599B1 (xx)
SG (1)	SG189975A1 (xx)
SI (1)	SI2640718T1 (xx)
TN (1)	TN2013000215A1 (xx)
TR (1)	TR201806652T4 (xx)
TW (1)	TWI516485B (xx)
UA (1)	UA112422C2 (xx)
UY (1)	UY33736A (xx)
WO (1)	WO2012065967A1 (xx)
ZA (1)	ZA201304430B (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102006050516A1 (de)	2006-10-26	2008-04-30	Bayer Healthcare Ag	Substituierte Dihydropyrazolone und ihre Verwendung
DE102010044131A1 (de)	2010-11-18	2012-05-24	Bayer Schering Pharma Aktiengesellschaft	Substituiertes Natrium-1H-pyrazol-5-olat
US10301289B2 (en) *	2012-05-08	2019-05-28	Bayer Pharma Aktiengesellschaft	Method for the preparation of triazole compounds
PE20160669A1 (es) *	2013-10-17	2016-08-04	Bayer Pharma AG	Formas de dosificacion farmaceutica que comprenden 1-[6-(morfolin-4-il)pirimidin-4-il]-4-(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olato de sodio
EP3569232A1 (en)	2014-09-26	2019-11-20	The Cleveland Clinic Foundation	Treating and preventing disease with tma and tmao lowering agents
CL2015003047A1 (es) *	2015-10-15	2016-06-17	Univ Chile	Método ex vivo para detectar precozmente injuria renal aguda en pacientes críticos, que comprende la mediciom en una muestra de tres proteinas como biomarcadores, factor de crecimiento fibroblástico 23, klotho y eritropoyetina
WO2018149929A1 (en) *	2017-02-16	2018-08-23	Bayer Pharma Aktiengesellschaft	Combination of reporter gene assays and transcriptional analysis
EP3888684A1 (en) *	2020-03-31	2021-10-06	Bayer Animal Health GmbH	Composition having improved voluntary acceptance

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR1519069A (fr)	1966-04-13	1968-03-29	Geigy Ag J R	Dérivés du sulfanilamide et leur préparation
GR63123B (en)	1975-12-11	1979-09-11	Lilly Co Eli	Preparation process of novel 1,4-diphenyl-3-pyrazolin-5-ones
US4075003A (en)	1975-12-11	1978-02-21	Eli Lilly And Company	Novel herbicidal method utilizing 1,4-diphenyl-3-pyrazolin-5-ones
PL103509B1 (pl)	1976-09-20	1979-06-30	Lilly Co Eli	Srodek chwastobojczy
US4663327A (en)	1984-05-23	1987-05-05	Bayer Aktiengesellschaft	1-heteroaryl-4-aryl-pyrazolin-5-ones
DE3443308A1 (de)	1984-11-28	1986-05-28	Bayer Ag, 5090 Leverkusen	1-heteroaryl-4-aryl-pyrazolin-5-one zur verwendung als arzneimittel
DE3527157A1 (de)	1985-07-30	1987-02-12	Bayer Ag	1-heteroaryl-4-aryl-pyrazol-derivate
DE4204919A1 (de)	1992-02-19	1993-08-26	Bayer Ag	Verfahren zur herstellung von 2-chlor-5-alkylaminomethyl-pyridinen
JPH0735361B2 (ja) *	1993-09-09	1995-04-19	日産化学工業株式会社	ヒドラゾン誘導体およびその製造方法
FR2725988B1 (fr)	1994-10-24	1997-01-24	Roussel Uclaf	Nouveaux derives de pyrazolones et pyrazoles acides, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
JPH10306077A (ja)	1997-05-07	1998-11-17	Daiichi Rajio Isotope Kenkyusho:Kk	ビピラゾール誘導体並びにこれを有効成分とする医薬および試薬
DE19909237A1 (de)	1999-03-03	2000-09-07	Merck Patent Gmbh	Pyrazol-3-on-derivate
US6878729B2 (en)	2001-05-04	2005-04-12	The Procter & Gamble Company	Medicinal uses of dihydropyrazoles
PT1407004E (pt)	2001-05-15	2009-08-31	Ortho Mcneil Janssen Pharm	Iniciação ex-vivo para produção de linfócitos t citotóxicos específicos de ligando-cd40 para tratar doenças autoimunes e alérgicas
JP4316893B2 (ja)	2001-05-16	2009-08-19	バーテックスファーマシューティカルズインコーポレイテッド	Ｓｒｃおよび他のプロテインキナーゼのインヒビター
IL160081A0 (en)	2001-09-21	2004-06-20	Solvay Pharm Bv	Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
AU2002359714B2 (en)	2001-12-18	2006-12-21	Merck Sharp & Dohme Corp.	Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
AU2003213673A1 (en)	2002-03-01	2003-09-16	Pintex Pharmaceuticals, Inc.	Pin1-modulating compounds and methods of use thereof
UY27813A1 (es) *	2002-05-31	2003-12-31	Smithkline Beecham Corp	Inhibidores de la peptido-desformilasa
US8124582B2 (en)	2002-12-06	2012-02-28	Fibrogen, Inc.	Treatment of diabetes
CA2522441A1 (en)	2003-03-27	2004-10-14	Emory University	Hif-1 inhibitors
WO2004089303A2 (en)	2003-04-03	2004-10-21	Merck & Co., Inc.	Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
US7456179B2 (en)	2003-05-01	2008-11-25	Panacea Pharmaceuticals, Inc.	Methods of treating ischemic related conditions
CN1842332A (zh) *	2003-06-30	2006-10-04	Hif生物公司	化合物、组合物及方法
AU2004275694B2 (en)	2003-06-30	2008-03-06	Bizbiotech Co., Ltd.	Compounds, compositions and methods
CA2614068A1 (en)	2004-06-29	2006-08-24	Massachusetts Institute Of Technology	Methods and compositions related to the modulation of intercellular junctions
DE102008020113A1 (de)	2008-04-23	2009-10-29	Bayer Schering Pharma Aktiengesellschaft	Substituierte Dihydropyrazolone und ihre Verwendung
CN101171235B (zh)	2005-03-16	2011-03-02	安万特药物公司	作为中枢神经系统活性剂的联吡唑类
DE102005019712A1 (de)	2005-04-28	2006-11-09	Bayer Healthcare Ag	Dipyridyl-dihydropyrazolone und ihre Verwendung
WO2007008541A2 (en)	2005-07-08	2007-01-18	Kalypsys, Inc.	Cellular cholesterol absorption modifiers
WO2007121687A1 (fr)	2006-04-26	2007-11-01	Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China	Dérivés du 4-méthyl-1h-diaryl pyrazole et leur utilisation comme médicaments
DE102006050515A1 (de)	2006-10-26	2008-04-30	Bayer Healthcare Ag	Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung
DE102006050513A1 (de)	2006-10-26	2008-04-30	Bayer Healthcare Ag	Substitiuierte Dihydropyrazolone und ihre Verwendung
DE102006050516A1 (de)	2006-10-26	2008-04-30	Bayer Healthcare Ag	Substituierte Dihydropyrazolone und ihre Verwendung
DE102010044131A1 (de)	2010-11-18	2012-05-24	Bayer Schering Pharma Aktiengesellschaft	Substituiertes Natrium-1H-pyrazol-5-olat

2010
- 2010-11-18 DE DE102010044131A patent/DE102010044131A1/de not_active Withdrawn
2011
- 2011-11-08 US US13/291,271 patent/US8653074B2/en active Active
- 2011-11-15 NZ NZ610614A patent/NZ610614A/en unknown
- 2011-11-15 AU AU2011331305A patent/AU2011331305B2/en active Active
- 2011-11-15 PT PT117849927T patent/PT2640718T/pt unknown
- 2011-11-15 SG SG2013030887A patent/SG189975A1/en unknown
- 2011-11-15 PL PL11784992T patent/PL2640718T3/pl unknown
- 2011-11-15 RS RS20180749A patent/RS57599B1/sr unknown
- 2011-11-15 MY MYPI2013700801A patent/MY167219A/en unknown
- 2011-11-15 AR ARP110104269A patent/AR083887A1/es not_active Application Discontinuation
- 2011-11-15 AP AP2013006922A patent/AP3429A/xx active
- 2011-11-15 KR KR1020137012680A patent/KR101984317B1/ko active IP Right Grant
- 2011-11-15 US US13/988,141 patent/US9533972B2/en active Active
- 2011-11-15 SI SI201131516T patent/SI2640718T1/en unknown
- 2011-11-15 EA EA201390703A patent/EA023103B1/ru not_active IP Right Cessation
- 2011-11-15 TR TR2018/06652T patent/TR201806652T4/tr unknown
- 2011-11-15 HU HUE11784992A patent/HUE038024T2/hu unknown
- 2011-11-15 LT LTEP11784992.7T patent/LT2640718T/lt unknown
- 2011-11-15 MX MX2013004797A patent/MX347670B/es active IP Right Grant
- 2011-11-15 UA UAA201307718A patent/UA112422C2/uk unknown
- 2011-11-15 DK DK11784992.7T patent/DK2640718T3/da active
- 2011-11-15 CN CN201180055239.3A patent/CN103270031B/zh active Active
- 2011-11-15 PE PE2013000943A patent/PE20140391A1/es active IP Right Grant
- 2011-11-15 CA CA2818002A patent/CA2818002C/en active Active
- 2011-11-15 PE PE2017002012A patent/PE20180324A1/es unknown
- 2011-11-15 EP EP11784992.7A patent/EP2640718B8/de active Active
- 2011-11-15 BR BR112013012223-4A patent/BR112013012223B1/pt active IP Right Grant
- 2011-11-15 CN CN201510059285.0A patent/CN104650047A/zh active Pending
- 2011-11-15 JP JP2013539223A patent/JP5918779B2/ja active Active
- 2011-11-15 ES ES11784992.7T patent/ES2675580T3/es active Active
- 2011-11-15 KR KR1020187005194A patent/KR20180023043A/ko not_active Application Discontinuation
- 2011-11-15 WO PCT/EP2011/070099 patent/WO2012065967A1/de active Application Filing
- 2011-11-16 UY UY0001033736A patent/UY33736A/es active IP Right Grant
- 2011-11-17 TW TW100141958A patent/TWI516485B/zh active
- 2011-11-17 JO JOP/2011/0347A patent/JOP20110347B1/ar active
2013
- 2013-04-30 CO CO13109274A patent/CO6741155A2/es not_active Application Discontinuation
- 2013-05-02 CR CR20130196A patent/CR20130196A/es unknown
- 2013-05-03 DO DO2013000096A patent/DOP2013000096A/es unknown
- 2013-05-07 IL IL226192A patent/IL226192A/en active IP Right Grant
- 2013-05-15 GT GT201300125A patent/GT201300125A/es unknown
- 2013-05-16 CL CL2013001390A patent/CL2013001390A1/es unknown
- 2013-05-16 MA MA35911A patent/MA34671B1/fr unknown
- 2013-05-16 CU CU2013000072A patent/CU20130072A7/es unknown
- 2013-05-16 EC ECSP13012627 patent/ECSP13012627A/es unknown
- 2013-05-17 TN TNP2013000215A patent/TN2013000215A1/fr unknown
- 2013-06-14 ZA ZA2013/04430A patent/ZA201304430B/en unknown
2014
- 2014-02-26 HK HK14101861.8A patent/HK1188782A1/xx unknown
2015
- 2015-11-23 HK HK15111529.0A patent/HK1210776A1/xx unknown
2018
- 2018-06-27 HR HRP20180993TT patent/HRP20180993T1/hr unknown
- 2018-06-28 CY CY20181100675T patent/CY1120375T1/el unknown

Also Published As

Publication number	Publication date
ECSP13012627A (es)	2013-07-31
CN103270031B (zh)	2015-06-17
CY1120375T1 (el)	2019-07-10
UA112422C2 (uk)	2016-09-12
RS57599B1 (sr)	2018-11-30
CA2818002C (en)	2019-01-15
PL2640718T3 (pl)	2018-08-31
NZ610614A (en)	2015-05-29
HRP20180993T1 (hr)	2018-08-10
MX347670B (es)	2017-05-03
DK2640718T3 (da)	2018-07-16
JOP20110347B1 (ar)	2021-08-17
IL226192A (en)	2016-06-30
CN103270031A (zh)	2013-08-28
US20120129857A1 (en)	2012-05-24
EA201390703A1 (ru)	2013-12-30
MA34671B1 (fr)	2013-11-02
HK1210776A1 (en)	2016-05-06
WO2012065967A1 (de)	2012-05-24
US20130310381A1 (en)	2013-11-21
US9533972B2 (en)	2017-01-03
KR20130131335A (ko)	2013-12-03
AP3429A (en)	2015-09-30
EP2640718A1 (de)	2013-09-25
EP2640718B1 (de)	2018-03-28
AU2011331305B2 (en)	2016-06-02
LT2640718T (lt)	2018-07-10
CR20130196A (es)	2013-08-06
EP2640718B8 (de)	2018-06-27
TW201307328A (zh)	2013-02-16
MY167219A (en)	2018-08-14
HUE038024T2 (hu)	2018-09-28
PE20180324A1 (es)	2018-02-13
ES2675580T3 (es)	2018-07-11
CO6741155A2 (es)	2013-08-30
BR112013012223B1 (pt)	2021-06-29
PT2640718T (pt)	2018-07-04
MX2013004797A (es)	2013-06-28
SI2640718T1 (en)	2018-08-31
CN104650047A (zh)	2015-05-27
TR201806652T4 (tr)	2018-06-21
DE102010044131A1 (de)	2012-05-24
TWI516485B (zh)	2016-01-11
GT201300125A (es)	2017-07-26
CL2013001390A1 (es)	2014-04-04
DOP2013000096A (es)	2013-06-15
EA023103B1 (ru)	2016-04-29
UY33736A (es)	2012-06-29
US8653074B2 (en)	2014-02-18
KR20180023043A (ko)	2018-03-06
KR101984317B1 (ko)	2019-05-30
AP2013006922A0 (en)	2013-06-30
AR083887A1 (es)	2013-03-27
AU2011331305A1 (en)	2013-06-06
SG189975A1 (en)	2013-06-28
CA2818002A1 (en)	2012-05-24
TN2013000215A1 (en)	2014-11-10
BR112013012223A2 (pt)	2020-03-10
IL226192A0 (en)	2013-07-31
ZA201304430B (en)	2014-12-23
JP5918779B2 (ja)	2016-05-18
JP2014500877A (ja)	2014-01-16
PE20140391A1 (es)	2014-03-29
CU20130072A7 (es)	2013-09-27

Publication	Publication Date	Title
AP3607A (en)	2016-02-26	Substituted imidazopyridazines
DK3342786T3 (en)	2021-09-27	Anti-dll3-antistof
AP3107A (en)	2015-01-31	5-Alkynyl-pyrimidines
HK1171452A1 (en)	2013-03-28	Substituted pyrrolidine-2-carboxamides -2-
EP2566479A4 (en)	2013-10-23	AZA-INDAZOLES
EP2640189A4 (en)	2014-03-19	3-deutero-pomalidomide
EP2651505A4 (en)	2014-06-11	ELECTROPORATION-INDUCED ELECTROSENSIBILIZATION
DK3466977T3 (en)	2022-04-11	Anti-vla-4-antistoffer
EP2641891A4 (en)	2014-07-23	PKC ACTIVATOR-
HK1188782A1 (en)	2014-05-16	Substituted sodium-1h-pyrazole-5-olate 1h--5-
AU4536P (en)	2013-04-30	TB01 Tibouchina urvilleana
AU4822P (en)	2014-06-11	FlatwaxwhiteGL Chamelaucium uncinatum
AU4931P (en)	2014-10-21	FlatwaxDarkGL Chamelaucium uncinatum
AU4932P (en)	2014-10-21	FlatwaxpinkGL Chamelaucium uncinatum
AU4937P (en)	2014-10-21	FlatinsulGL Myoporum insulare
AU2010165V (en)	2010-10-09	Silversunrise Conostylis candicans
AU2010194V (en)	2010-11-23	CalpenGL Calothamnus quadrifidus
GB201000020D0 (en)	2010-02-17	Velcrose
GB201000066D0 (en)	2010-02-17	1Velcrose
GB201000166D0 (en)	2010-02-24	Doordeadman
GB201000203D0 (en)	2010-02-24	Formits
GB201000246D0 (en)	2010-02-24	Head-kase
GB201000262D0 (en)	2010-02-24	Flexishaft
GB201000426D0 (en)	2010-02-24	Earbling
GB201000547D0 (en)	2010-03-03	Jurasic